Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Jun on Results of Study in Cryptogenic Hepatocellular Carcinoma

Tomi Jun, MD
Published: Friday, Apr 21, 2017



Tomi Jun, MD, Stanford University School of Medicine, discusses the results of a study of cirrhosis and long-term survival in patients with cryptogenic hepatocellular carcinoma (HCC).

This was a multi-center, international cohort of about 4000 patients out of the United States and Taiwan that aimed to evaluate the significantly lower rates of cirrhosis and worse long-term survival in patients with cryptogenic HCC compared with viral etiologies.

Although patients with cryptogenic HCC showed less cirrhosis, survival was significantly lower than what was shown in patients with hepatitis b- and hepatitis c-related HCC.
 

<<< View more from the 2017 International Liver Congress



Tomi Jun, MD, Stanford University School of Medicine, discusses the results of a study of cirrhosis and long-term survival in patients with cryptogenic hepatocellular carcinoma (HCC).

This was a multi-center, international cohort of about 4000 patients out of the United States and Taiwan that aimed to evaluate the significantly lower rates of cirrhosis and worse long-term survival in patients with cryptogenic HCC compared with viral etiologies.

Although patients with cryptogenic HCC showed less cirrhosis, survival was significantly lower than what was shown in patients with hepatitis b- and hepatitis c-related HCC.
 

<<< View more from the 2017 International Liver Congress


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x